2,6-Dimethylmescaline, or simply dimethylmescaline (DMe-M), also known as 2,6-dimethyl-3,4,5-trimethoxyphenethylamine, is a serotonin receptor modulator of the phenethylamine and scaline families related to mescaline. It is the 2,6-dimethyl derivative of mescaline.
The drug shows affinity for the serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> receptors (K<sub>i</sub> = 45nM, 879nM, and 1,002nM, respectively). These affinities were 66-fold, 5.2-fold, and 7.7-fold higher than those of mescaline, respectively. The drug has not been tested in animals or humans.
2,6-Dimethylmescaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013. The source of the information cited by Trachsel and colleagues was a personal communication with David E. Nichols in 2010. It is not a controlled substance in Canada as of 2025.